REPL Live signals | Maximize Profits with Getagraph.com

BUY 157547 min ago

@ $6.89

Issued: 14 Feb 2024 @ 14:38

Return: -23.51%

Previous signal: Feb 14 - 13:38

Previous signal: Sell

Return: -2.96 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	748 268
Average Volume	909 452
Market Cap	323.66M
EPS	$0 ( 2024-05-16 )
Next earnings date	( $-0.870 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.630
ATR14	$0.0110 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-16	Sarchi Christopher	Sell	2 218	Common Stock
2024-05-16	Schwendenman Andrew	Sell	2 298	Common Stock
2024-05-16	Love Colin	Sell	17 615	Common Stock
2024-05-16	Astley-sparke Philip	Sell	37 928	Common Stock
2024-05-16	Coffin Robert	Sell	11 464	Common Stock

INSIDER POWER
66.45
Last 98 transactions
Buy: 2 588 053 \| Sell: 532 253

Volume Correlation

Long: 0.35 (neutral)

Short: 0.33 (neutral)

Signal:(57.345) Neutral

Replimune Group Inc Correlation

10 Most Positive Correlations
FIVE	0.89
VERV	0.876
QTRX	0.87
EDIT	0.861
ALKS	0.86
WKHS	0.86
RKDA	0.859
CDZIP	0.853
PTPI	0.853
ATRC	0.85

10 Most Negative Correlations
GOOG	-0.839
GOOGL	-0.837
VFF	-0.815
WIRE	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Replimune Group Inc Correlation - Currency/Commodity

-0.12
( neutral )

-0.13
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.07
( neutral )

Replimune Group Inc Financials

Annual	2024
Revenue:	$0
Gross Profit:	$-2.66M (0.00 %)
EPS:	$-3.24

FY	2024
Revenue:	$0
Gross Profit:	$-2.66M (0.00 %)
EPS:	$-3.24

FY	2023
Revenue:	$0
Gross Profit:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2022
Revenue:	$0
Gross Profit:	$-4.58M (0.00 %)
EPS:	$-2.26

Financial Reports:

No articles found.

Replimune Group Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.